

A

- **Abrams S, Griffin I, Hawthorne K.(2006):**Relationships among vitamin D levels, parathyroid hormone, and calcium absorption in young adolescents. *J Clin Endocrinol Metab* ; 90(10): 5576-81.

- **Adams, J.S. and M. Hewison.(2008):** Unexpected actions of vitamin D:new perspectives on the regulation of innate and adaptive immunity. *Nat Clin Pract Endocrinol Metab.* 4(2): p. 80–90.

- **Alarcon GS,Friedman AW,Straaton KV et al;(1999):**Systemic Lupus erythematosus in three ethnic groups:III. Acomparison of characteristics early in the natural history of the LUMINA cohort. Lupus in minority populations:Nature vs Nurture. *Lupus*;8:197-209.

- **Alele JD, Kamen DL.(2010):**The importance of inflammation and vitamin D status in SLE-associated osteoporosis. *Autoimmun Rev*;9:137-9.

- **Anaizi Nasr. (2010):** Rediscovering vitamin D. *Libyan J Med* , 5: 5648 - DOI: 10.3402/ljm.v5i0.5648

- **Appel G and D'Agati V.(2001):**Renal involvement in multisystem disease. In: Massry S, Glassock R, editors. *Textbook of nephrology*, 4th ed. Philadelphia: Lippincott Williams and Wilkins ; 777-86.

- **Aringer M, Steiner G, Graninger W.(2007):** Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. *Arthritis Rheum Jan*; 56(1): 274–9.

- **Armas LA, Hollis BW, Heaney RP.(2004):** Vitamin D2 is much less effective than vitamin D3 in humans. *J Clin Endocrinal Metab* 2004;89:5387–5391.

- **Arnson Y, Amital H, Shoenfeld Y.(2007):** Vitamin D and autoimmunity: new etiological and therapeutic considerations. *Ann Rheum Dis* 2007; 66:1137-42.

- **Arnson Y,Gringauz I, Itzhaky D, Amital H. (2012.)**
Vitamin D deficiency is associated with poor outcomes and increased mortality in severely ill patients.*QJM*, Jul;105(7):633-9.

B

- **Barnes TC, Bucknall RC. (2004):**vitamin D deficiency in patients with systemic lupus erythematosus . *Rheumatology* ;43;393-394.

- **Basile LA, Taylor SN, Wagner CL et al;(2007):** Neonatal vitaminD status at birth at latitude 32 degrees 72': evidence of deficiency. *J Perinatol*;27(9):568-71.

- **Ben-Zvi I, Aranow C, Mackay M, Stanevsky A, Kamen DL, et al; (2010):** The Impact of Vitamin D on Dendritic Cell Function in Patients with Systemic Lupus Erythmatosus. *PLoS ONE* 5(2): e9193.doi:10.137/journal.pone.0009193.

- **Bischoff-Ferrari, H., Vitamin D.(2009):** what is an adequate vitamin D level and how much supplementation is necessary? Best Pract Res Clin Rheumatol, 23(6): p. 789–95.

- **Boddaert J, Huong DL, Amoura Z, Wechsler B, Godeau P, Piette JC.(2004):**Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. *Medicine (Baltimore)*. Nov ;83(6):348-59.

- **Bombardier C, Gladman DD, Urowitz MB, Caron D, and Chang CH. (1992):** The committee on prognosis studies in SLE. Deviation of the SLEDAI: A disease activity for lupus patients. *Arthritis rheum* 35:630-640.

- **Boonen S, Lips P, Bouillon R, et al;(2007):** Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative meta analysis of randomized controlled trials. *J Clin Endocrinol Metab* ;92:1415–1423.

- **Borba V, Vieira J, Kasamatsu T.(2008):** Vitamin D deficiency in patients with active systemic lupus erythematosus. *Osteoporos Int* ; 20:427–33.

- **Bosch X.(2011):** Systemic lupus erythematosus and the neutrophil. *N Engl J Med*. Aug 25 ;365(8):758-60.

- **Boumpas D, Furie R, Manzi S.(2003):** A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. *Arthritis Rheum* Mar; 48(3): 719–27.

- **Brams P., Black A., Padlan E.A., et al., (2001)** : A humanized anti-human CD 154 monoclonal antibody blocks CD154-CD 40 mediated human B cell activation.; 1 (2): 277-94.

- **Bringham FR, Demay MB, Kronenberg HM .(2008):** Hormones and Disorders of Mineral Metabolism. In Williams Textbook of Endocrinology, 11 ed. Philadelphia: Elsevier

- **Broder AR, Tobin JN, Putterman C.(2010)** :Disease-specific definitions of vitamin D deficiency need to be established in autoimmune and non-autoimmune chronic diseases: a retrospective comparison of three chronic diseases. Arthritis Res Ther. 2010;12(5):R191. Epub 2010 Oct 14.

- **Broder A, Khattri S, Patel R, Putterman C .(2011):** Under treatment of Disease Activity in Systemic Lupus Erythematosus Patients with End stage Renal Failure Is Associated with Increased All-cause Mortality. *J Rheumatol.* Nov ;38(11):2382-9.

- **Broe K, Chen T, Weinberg J.(2007):** A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. *J Am Geriatr Soc* ; 55:234 –9.

- **Bujan S, Ordi- Ros J, Paredes J, Mauri M, Matas L,Cortes J and Vilardell M. (2003):** Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. *Ann Rheum Dis*; 62 (9):859- 865.

- **Buratti S, Szer I, Spencer C.(2001):** Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus .*J Rheumatol* ; 28: 2103.

C

- **Carvalho JF, Blank M, Kiss E et al ;(2007):** Anti-vitamin D, vitamin D in SLE: preliminary results. *Ann N Y Acad Sci.* ;1109:550-7.
- **Cantorna MT, Mahon B.(2004):** Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. *Exp Bio Med (Maywood)* ; 229(11):1136-42.
- **Chatfield S, Brand C, Ebeling P.(2007):**Vitamin D deficiency in general medical in patients in summer and winter. *Intern Med J*; 37: 377–82.
- **Chen S, Sims GP, Chen XX, et al;(2007):** Modulatory effects of 1,25-dihydroxy vitamin D3 on human B cell differentiation.*J Immunol* ; 179:1634-1647.
- **Christie M Bartels and Daniel Muller,(2010):** systemic lupus erythematosus ; Department of Medicine, University of Wisconsin School of Medicine and Public Health..
- **Coblyn J.S., and Weinblatt M.E.(1997):** Rheumatic diseases and the heart. "Systemic Lupus Erythematosus", In: Heart disease. " A textbook of cardiovascular medicine. Edited by: Braunwald E., 5th edition; Chap. 56: P. 1776.
- **Cohen M.R. and Isenberg D.A. (1996):** Ultraviolet irradiation in systemic lupus erythematosus: Friend or foe? *Br. J. Rheumatol.*;35: 1002.

- **Contreras G, Pardo V, Leclercq B.(2004):** Sequential therapies for proliferative lupus nephritis. *New Eng J Med* Mar 4; 350(10): 971–80.

- **Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW.(2007):** Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. *Arthritis Rheum.* Apr ;56(4):1251-62.

- **CostenbaderKH , Feskanich D, Benito-Garcia E ,Holmes M, Karlson E.(2008):**Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. *Ann Rheum Dis* Apr; 67(4):530-5.

- **CushJ,Stein C. (2005):**Rheumatology Diagnosis and Therapeutics, 2nd ed. Philadelphia: Lippincott Williams & Wilkins .

- **Czeizel A.(1990):** A case-control analysis of the teratogenic effects of co-trimoxazole. *Reprod Toxicol*;4(4):305-13.

- **Cutolo M .(2008) :** Vitamin D and autoimmune rheumatic diseases.*Arthritis Research & Therapy* , **10**:123 (doi:10.1186/ar2552).

- **Cutolo M., Otsa K.(2008):** Vitamin D, immunity and lupus. *Lupus*;17:6–10.

- **Cutolo M, Otsa K, Laas K et al ;(2006):** Circannual vitamin D serum levels and disease activity in rheumatoid arthritis : Northern versus Southern Europe.*Clin Exp Rheumatol* ;24:702-704.

▪ **Cutolo M, Otsa K, Paolino S, et al;(2009):** Vitamin D involvement in rheumatoid arthritis and systemic lupus erythaematosus. *Ann Rheum Dis*.;68(3):446-7.

D

▪ **Dacie JV and Lewis SM. (1985):** Practical Haematology 8th ed. Churchill Livingstone.;210-60

▪ **Damanhouril.(2009):** Vitamin D deficiency in Saudi patients with systemic lupus erythematosus. *Saudi Med J* ; 30(10): 1291-5.

▪ **Danchenko N, Satia JA, Anthony MS.(2006):** Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. *Lupus*. ;15(5):308-18.

▪ **David W, Xamont D and Mai Kirn Lai. (2006):**Systemic lupus erythematosus. *Rheum Dis Clin North Am*. ; 32(1): 150-160.

▪ **DeLuca H.(2004):** Overview of general physiologic features and functions of vitamin D. *Am J Clin Nutr* ; 80: 1689.

▪ **Deluca HF, Cantorna MT.(2001):** Vitamin D – its role and uses in immunology. *FASEB Journal* ; 15:2579-85.

▪ **Doria A, Arienti S, Rampudda M.,(2008):**Preventive strategies in systemic lupus erythematosus. *Autoimmunity Rev*; 7: 192–7.

- **Dorner T, Kaufmann J, Wegener W.(2006)** : Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. *Arthritis Res Therapy* ; 8(3): 74.

E

- **Edworthy S.M. (2001)**: "Clinical manifestations of systemic lupus erythematosus". In: Kelley's textbook of Rheumatology. Edited by: Ruddy S., Harris E.D., Sledge C.B, 6th edition.; Saunders, Philadelphia. Chap. 74: P. 11 OS-1123.
- **EdworthySM.(2005)**: Clinical Manifestations of Systemic Lupus Erythematosus. In: Harris ED, et al, eds. Kelley's Textbook of Rheumatology. 7th ed. Saunders:1201-24.
- **Emori A., Matsushima E., Aihora O., Ohta K., Koime R., Miyasaka N. and Kato M. (2005)**: Cognitive dysfunction in systemic lupus erythemtaosus. *Psych Clin Neuroscience.*, 59: 584-589.

F

- **Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S.(2010)**: Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. *Arthritis Care Res (Hoboken)*. Jun ;62(6):873-80.

▪ **Fragoso T. S., Dantas A.T., Marques C.D.L et al;(2010):** 25-Hydroxyvitamin D3 levels in patients with systemic lupus erythematosus and its association with clinical parameters and laboratory tests. *Rev. Bras. Reumatol.* vol.52 no.1 São Paulo Jan./Feb.

G

▪ **Garton M.J. and Isenberg D.A.(1997):** Clinical features of lupus myositis versus idiopathic myositis: A review of 30 cases. *Br. J. Rheumatol.*; 36: 1067.

▪ **Gauzzi, M.C., et al., (2005):**Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. *J Immunol.* 174(1): p. 270–276.

▪ **Ginde AA, Liu MC ,Camargo CA.(2009):** Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. *Arch Intern Med*;169(6):626-32.

▪ **Gitelman M, Miller M.(2007):**Systemic lupus erythematosus. In: Behrman R, Kliegman R, Jenson H, editors. *Nelson textbook of pediatrics*, 18th ed. Philadelphia: Saunders W.

▪ **Gladman D.D. and Urowitz M.B.(1997):** "Systemic lupus erythematosus, clinical and laboratory features". *Primer on the Rheumatic Diseases*, 11th edition. Klippel J.H. (editor), Chap. 19:215-257.

H

- **Hahn BH.(2005):** Management of Systemic Lupus Erythematosus : In: Harris ED, et al, eds. *Kelley's Textbook of Rheumatology*. 7th ed. Saunders; 1225-47.
- **Hahn BH, Karpouza GA, Tsao BP.(2005):**Pathogenesis of systemic lupus erythematosus. In: Harris ED, et al,eds. *Kelley's Textbook of Rheumatology*. 7th ed. Philadelphia, Pa: Saunders;1174-1200.
- **Harley J.B., Sestak A.I, and Willis L.F. (1992):**A model for disease heterogeneity in systemic lupus erythematosus. *Arthritis Rheum*. 32: 826.
- **Helming L, Bose J, Ehrchen J et al ; (2005):** 1 alpha,25- dihydroxy vitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. *Blood* ; 106: 4351-4358.
- **Hochberg M.(1997):**Updating the American College of Rheumatology revised criteria for the classification of systemic lupuserythematosus. *Arthritis Rheum* ; 40: 1725.
- **Holick MF.(2006):** High prevalence of vitamin D inadequacy and implications for health. *Mayo Clin Proc*;81:353–373.
- **Holick MF.(2007)** Vitamin D deficiency. *N Engl J Med* 2007; 357: 266–281.
- **Holick M , Chen T.(2008):** Vitamin D deficiency: a worldwide problem with health consequences. *Am J Clin Nutr* ; 87(suppl): 1080S– 6S.

- **Huang C, Wu M, Wu J.(2002):**No association of vitamin D receptor gene start codon fok 1 polymorphisms in Chinese patients with systemic lupus erythematosus. *J Rheumatol* ;29: 1211–3.

- **Huisman AM,White KP, Algra A et al; (2001):** vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. *J Rheumatol* ; 28:2535-2539.

- **Huybers S, Naber TH, Bindels RJ, Hoenderop JG.(2007):** Prednisolone induced Ca²⁺ malabsorption is caused by diminished expression of the epithelial Ca²⁺ channel TRPV6. *Am J Physiol Gastrointest Liver Physiol* ;292:G92–G97.

- **Hyppönen E, Boucher BJ, Berry D, Power C .(2008) :**Insulin-like growth factor I, 25-hydroxyvitamin D and metabolic syndrome mid-life: the British 1958 birth cohort study. *Diabetes* 57[2]: 298–305.

I

- **Ibanez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB ;(2011):** Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. *J Rheumatol*. Jan ;38(1):60-3.

- **Illei G, Austin H, Crane M.(2001):** Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. *Ann Intern Med* Aug 21; 135(4): 248–57.

J

- **Jennifer K , Bevra H.,(2007):**Systemic lupus erythematosus: modern strategies for management – a moving target. *J berh* ; 21(6): 971-87.
- **Jones BJ, Twomey PJ. ,(2008):** Issues with vitamin D in routine clinicalpractice. *Rheumatology* ; 47:1267-68

K

- **Kaisho T, Takeda K, Tsujimura T et al., (2001):**L kappa B kinase alpha is essential for mature B cell development and function. *J Exp Med.* 193: 417-426.
- **Kamen DL,(2010):** Vitamin D in lupus: *Bull NYU Hosp Jt Dis.*;68(3):218-22.
- **Kamen DL, Aranow C.(2008) :**The link between vitamin D deficiency and systemic lupus erythematosus. *Curr Rheumatol Rep.*;10(4):273-80.
- **Kamen DL, Cooper GS, Bouali H, Shaftman Sr, Hollis BW , Gilkeson GS, (2006):** vitamin D deficiency in systemic lupus Erythematosus. *Autoimmune Rev*;5:114-117.
- **Kasitanon N, Magder LS, Petri M.(2006):** Predictors of survival in systemic lupus erythematosus. *Medicine (Baltimore).* May ;85(3):147-56

- **Khan I, Tsokos G, Kammer G.(2003):** Abnormal B cell signal transduction in systemic lupus erythematosus. *Curr. Dir. Autoimmun.*; 6: 89–104.
- **Khazai N., Judd E.S., and Tangpricha V.,(2008):** Calcium and Vitamin D: Skeletal and Extraskelatal Health *Curr Rheumatol Rep.* April ; 10(2): 110–117.
- **Kilkinen, A., et al.,(2009):** Vitamin D status and the risk of cardiovascular disease death. *Am J Epidemiol.* 170(8): p. 1032–9.
- **Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ,(2008):** Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey2001 to 2004)*Am J Cardiol.* 2008 Dec 1;102(11):1540-4.
- **Kirous K, Lee C, George S,(2005):.** Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. *Arthritis Rheum* ; 52: 1491-1503.
- **Klippel JH (1994):**Systemic lupus erythematosus.In: *Rheumatology.* John H. Klippel and Paul A. Diepp (eds). 1st edition. Mosby, London, Philaelfia. Pp: 1230.

L

- **Lanzavecchia A, Sallusto F.(2001):** Regulation of T cell immunity dendritic cells. *Cell*; 106:263-266.

- **Lee C, Almagor O, Dunlop D.(2007):**Self-reported fractures and associated factors in women with systemic lupus erythematosus. *J Rheumatol* ; 34: 2018.
- **Leventis P, Patel S.(2008):** Clinical aspects of vitamin D in the management of rheumatoid arthritis. *Rheumatology* 2008; 47:1617-21.
- **Li LH, Yuan H , Pan HF ,Li WX, Li XP ,Ye DQ (2010):** Role of the Fc gamma receptor IIIA- V/F 158 polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis : a meta-analysis.*Scand J Rheumatol* ; 39:148-54.
- **Linker-Israeli M ,Elstner E, KLinenberg JR et al.(2001):**Vitamin D 3 and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE derived PBMC. *Clin Immunol* ;99:82-93.
- **Liu, P.T., et al., (2006):**Toll-like receptor triggering of a vitamin D mediated human antimicrobial response. *Science*. 311 (5768): p. 1770–3.
- **Looney R, Anolik J, Sanz I.(2004):** B cells as therapeutic targets for rheumatic disease. *Curr Opin Rheumatol* ; 16: 180–5.

M

- **Magid MS, Kaplan C and Sammaritano LR .(1998):** Placental pathology in systemic lupus erythematosus: A prospective study. *Am. J. Obstet. Gynecol.*; 179: 226.
- **Mahon BD ,Wittke A ,Weaver V et al.(2003):** The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. *J Cell Biochem* ;89 : 922-932.

- . **Mandell B.F. and Hoffman G.S. (2001):** Rheumatic diseases and the cardiovascular system. In: "Heart disease". A textbook of cardiovascular medicine. 6th ed., W.B. Saunders Company.; Chap.67: P. 2199.
- **Manger, Seelen, Marc A; Trouw, L A; Daha, M R . (2003):** Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Current Opinion in Nephrology and Hypertension: November 2003 - Volume 12 - Issue 6 - pp 619-624.
- **Marco E Cutillas , Varela MM, Marquina-Vila A and Grant WB. (2010):** Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region Lupus 19, 810–814.
- **Marisa SK, Barry LM, Robert K, PharmD, Thomas JA Lehman, Daniel Ranch and Norman T Ilowite.(2004):**Systemic Lupus Erythematosus, Current Opinion in Rheumatology.;16:577-587
- **Marques C. D., Dantas A. T. , FragosoT. S. , Duarte4 Â. B. (2010):**The importance of vitamin D level in autoimmune diseases. Bras J Rheumatol 2010;50(1):67-80 73.
- **Mattner F, Smiroldo S, Galbiati F, et al.(2000):** Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol ; 30:498-508.
- **Mc Donagh J.E, Khamashta MA and Menon S.(1997):**A young woman with SLE: Diagnostic and therapeutic challenges. Lupus; 6: 633.

- **Moder K.G., Miller T.D. and Tazelaar H.D. (1999):** Cardiac involvement in systemic lupus erythematosus. Mayo. Clin. Proc.; 74(3): 275- 284.
- **Mok C , Lau C (2003):** Pathogenesis of systemic lupus erythematosus. J Clin Pathol ; 56: 481–90.
- **Mok C, Mak A, Chu W.(2005):** Long-term survival of southern Chinese patients with systemic lupus erythematosus: A prospective study of all age groups. Medicine; 84: 218-24.
- **Mok CC, Poon WL, Lai JP, Wong CK, Chiu SM,Wong CK, Chiu SM, wong Ck, et al . (2010):**Metabolic syndrome, endothelial injury ,and subclinical atherosclerosis in patients with systemic lupus erythematosus .Scand J Rheumatol ;39:42-9.
- **Mouyis M, Ostor A, Crisp A.(2008):** Hypovitaminosis D among rheumatology outpatients in clinical practice. Rheumatology ; 47:1348–51.
- **Muller K, Kriegbaum N, Baslund B.(1995):** Vitamin D metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D in patients with systemic lupus erythematosus. Clin Rheumatol ; 14: 397–400.

N

- **Nagpal S, Na S, Rathnachalam R .(2005):** Noncalcemic actions of vitaminD receptor ligands. Endocrine Reviews ; 26(5):662-87.

O

- **Omran G, Masoompour S, Sadegholvaad A. (2006):** Effect of menopause and renal function on vitamin D status in Iranian women. *East Mediter Health J* 2006; 12(2): 160-9.
- **Ozakia Y, Nomura S, Nagahama M. (2000):** Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus. *Nephron* ; 85:86–91.

P

- **Parks CG, Cooper GS, Hudson LL, Dooley MA, Treachvell EL, St Clair EW, Gilkeson GS and Pandey JP. (2005):** Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T-lymphocyte associated antigen 4 genotype. *Arthritis Rheum.* Apr; 52(4): 1148-59.
- **Peggy W., Elisa R.Y., Alan D.R., Dorothy D. D., et al. (2009):** 25-Hydroxyvitamin D and Cardiovascular Risk Factors in Women with Systemic Lupus Erythematosus *Arthritis Rheum.* October 15; 61(10): 1387–1395.
- **Penna G, Adorini L. (2000).** 1 Alpha,25-dihydroxyvitamin D₃ inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. *J Immunol* ; 164:2405-2411.

- **Perlstein TS, Pande R, Berliner N, Vanassa G.J (2011):** Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. *Blood* March 10, vol. 117 no. 10
- **Petri M (1995):** Clinical features of systemic lupus erythematosus (review). *Curr. Opin. Rheumatol.*; 7: 395.
- **Petri M A., Bello K. J., Fang, H. M, (2010):** Vitamin D Levels Are Positively Associated with Complement among Patients with SLE. *Arthritis Rheum* ;62 Suppl 10 :1180.

R

- **Rahman P, Gladman DD and Urowitz MB. (1998):** Clinical predictors of fetal outcome in systemic lupus erythematosus. *J. Rheumatol.*; 25:126.
- **Rahman A and Isenberg DA. (2008):** Systemic lupus erythematosus. *N Engl J Med.* Feb 28 ;358(9):929-39.
- **Redlich K, Ziegler S, Kiener H.(2000):** Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. *Ann Rheum Dis* ; 59: 308–10.
- **Reefman P, Kuiper H, Limburg PC et al., (2007):** Type I interferons are involved in the development of UVB induced inflammatory skin lesions in Systemic Lupus Erythematosus (SLE) patients. *Ann Rheum Dis.*, 57:411.

- **Richter CM, Steiner G, Smolen JS and Isenberg DA. (1998):**Erosive arthritis in systemic lupus erythematosus: Analysis of a distinct clinical and serological subset. Br. J. Rheumatol.; 37:421.
- **Ritterhouse L.L., Crowe S.R, Niewold T.B., Kamen D.L : et al ;(2011):** Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus,Ann Rheum Dis. September; 70(9): 1569–1574.
- **Robinson P, Hogler W, Craig M.(2006):** The re-emerging burden of rickets: a decade of experience from Sydney. Arch Dis Child 2006; 91: 564-8.
- **Rothfield NF. (1993):**SLE: clinical aspects and treatment. Arthritis and Allied conditions. A Text book of Rheumatology 12th ed.l 155-1177.
- **Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxo A, Aguirre C.(2008):** Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology; 47:920-3.

S

- **Salmon JE and Kimberly RP. (2000):**Systemic Lupus Erythematosus" In: Manual of Rheumatology and outpatient orthopedic disorders. "Diagnosis and therapy". 4th edition. Paget S.A., Gibofsky A.', and Beery J.F. (editors): 236-251.

- **Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A and Hughes GR;(2005):**Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. *J Rheumatol.*, 30 (5): 985-992.

- **Sarzi-Puttini P, Atzeni F, Iaccarino L(2005):** Environment and systemic lupus erythematosus: An overview. *Autoimmunity* 2005; **38(7):** 465-72.

- **Sasigarn A, Renee F, John D. (2008):**Prevalence of vitaminDdeficiency and insufficiency in children with osteopenia or osteoporosis referred to a Pediatric Metabolic Bone Clinic. *Pediatrics* ; 121(6):e1585-e90.

- **Scheven E. von & Burnham J. M. (2011):**Vitamin D Supplementation in the Pediatric Rheumatology Clinic. *Curr Rheumatol Rep*,13:110–116.

- **Schmajuk G, Yelin E, Chakravarty E, Nelson LM,(2010):** Panopolis P, Yazdany J. Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. *Arthritis Care Res (Hoboken)*. Jul ;62(7):993-1001

- **Schur PH (1993):** "Clinical features of systemic lupus erythematosus. ". In: *Kelley's Textbook of Rheumatology*, 4th edition. By: Kelley W.N., Harris E.D., Ruddy S., and Sledge C.B.(eds.); W.B. Saunders Company, Philadelphia, London, Toronto. Chap. 61.: P. 1030-1039.

- **Sestak AL, Fürnrohr BG, Harley JB, Merrill JT, Namjou B.(2011):**The genetics of systemic lupus erythematosus and implications for targeted therapy. *Ann Rheum Dis.* Mar ;70 Suppl 1:i37-43.

- **Sheng C, Sims G, Chen X.(2007):** Modulatory effects of 1,25-dihydroxy vitamin D3 on human B cell differentiation: *J Immunol* ; 179: 1634- 47.

- **Shoenfeld N, Amital H, Shoenfeld Y(2009):**The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. *Nat Clin Pract Rheumatol*;5(2):99-105.

- **Siebert CE, Daha MR, Lobatto S, van der Voort EA and Breedveld FC, (1992):** IgG autoantibodies to C1q do not detectably influence complement activation *in vivo* and *in vitro* in systemic lupus erythematosus. *Immunol Res*; 11:91–97.

- **Singh A. and Kamen DL.(2012):**Potential benefits of vitamin D for patients with systemic lupus erythematosus.*Dermato-Endocrinology* April/May/June 4:2, 146–151.

- **Sontheimer RD .(1996):** Photo-immunology of lupus erythematosus and dermatomyositis: A speculative review. *Photochem. Photobiol.*; 63: 583.

- **Steineberg AD .(1992):** "concepts of pathogenesis of SLE". *Clin. Immunol. Immunopathol.*; 63(1): 19-25.

- **Symmons DP.(1995):** Frequency of lupus in people of African origin. *Lupus.* Jun 1995;4(3):176-8.

▪ **Szodoray P, Nakken B, Gaal J, Jonsson R, Szegedi A, Zold E et al(2008):** The complex role of vitamin D in autoimmune diseases. Scand J Immunol ;68(3):261-9.

▪ **Szodoray P , Horvath IF ,Papp G ,Barath S ,Gyimesi E , Csathy L ,et al.(2010):** The immunoregulatory role of vitamins A ,D and E in patients with primary Sjogren`s syndrome. Rheumatology (Oxford) ;49:211-17.

T

▪ **Takiishi, T., et al.,(2010):** Vitamin D and diabetes. Endocrinol Metab ClinNorth Am. June39(2): p. 419–46, table of contents.

▪ **Tokunaga M, Saito K, Kawabata D.(2007):** Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007 Apr; 66(4): 470–5.

▪ **Toloza S, Cole D, Gladman D.(2009):** Vitamin D insufficiency in a large female SLE cohort. Lupus 2009; 0: 1–7.

V

▪ **Vacca A, Cormier C, Piras M.(2009):** Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis and SLE . J Rheumatol 2009; 36: 1924-9.

W

- **Wajed J, Ahmad Y, Durrington PN, Bruce IN.(2004):**Prevention of cardiovascular disease in systemic lupus erythematosus proposed guidelines for risk factor management. *Rheumatology (Oxford)*. Jan ;43(1):7-12.

- **Wallace D.(2007):**Antimalarial Therapies. In: Wallace DJH & BH (eds.). *Dubois' Lupus Erythematosus*, 7th ed. Philadelphia: Lippincott Williams and Wilkins ; 1152–74.

- **Wallace DJ and Metzger AL. (1997):**Systemic Lupus Erythematosus: Clinical aspects and treatment. In: *Arthritis and allied conditions: A ' textbook of rheumatology*. Edited by: William J. Koopman, and Daniel J. McCarty. 13th edition. Chap. 69; P. 1319.

- **Walz Le Blanc BA, Dagenais P and Urowitz MB (1994):**Methotrexate in systemic lupus erythematosus. *J. Rheumatol.*;21: 836.

- **Wang B, Gladman DD and Urowitz MB. (1998):** Fatigue in lupus is not correlated with disease activity.. *J. Rheumatol.*;25: 892.

- **Wang L, Yang Y, Chiang B.(2003):** Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. *J.Microbiol. Immunol. Infect*; 36: 203-8.

- **WangT.J., et al.,(2008):** Vitamin D deficiency and risk of cardiovascular disease. *Circulation*,117(4): p. 503–11.